Tautomycin suppresses growth and neuroendocrine hormone markers in carcinoid cells through activation of the Raf-1 pathway

American Journal of Surgery

Volumn 197, Issue 3, 2009, Pages 313-319

  Pinchot, Scott N ^a   Adler, Joel T ^a   Luo, Yinggang ^b   Ju, Jianhua ^b   Li, Wenli ^b   Shen, Ben ^b   Kunnimalaiyaan, Muthusamy ^a   Chen, Herbert ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

Carcinoid tumor; Extracellular regulated kinase pathway; Ref 1; Targeted therapies; Tautomycin

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; N [5 (3 DIMETHYLAMINOBENZAMIDO) 2 METHYLPHENYL] 4 HYDROXYBENZAMIDE; PROTEIN P21; PROTEIN P27; RAF PROTEIN; TAUTOMYCIN;

ARTICLE; CARCINOID; CELL CYCLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG TARGETING; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; GROWTH INHIBITION; HUMAN; HUMAN CELL; NEUROENDOCRINE TUMOR; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; TREATMENT RESPONSE; TUMOR CELL; TUMOR GROWTH; WESTERN BLOTTING;

CARCINOID TUMOR; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; ENZYME INHIBITORS; HUMANS; NEUROSECRETORY SYSTEMS; PROTO-ONCOGENE PROTEINS C-RAF; PYRANS; SIGNAL TRANSDUCTION; SPIRO COMPOUNDS; TUMOR MARKERS, BIOLOGICAL;

EID: 60549091925     PISSN: 00029610     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjsurg.2008.10.007     Document Type: Article

References (27)

1. Sippel R.S., and Chen H. Carcinoid tumors. Surg Oncol Clin North Am 15 (2006) 463-478
2. Musunuru S., Carpenter J.E., Sippel R.S., et al. A mouse model of carcinoid syndrome and heart disease. J Surg Res 126 (2005) 102-105
3. Pinchot S.N., Pitt S.C., Sippel R.S., et al. Novel targets for the treatment and palliation of gastrointestinal neuroendocrine tumors. Curr Opin Invest Drugs 9 (2008) 576-582
4. Kulke M., and Mayer R. Carcinoid tumors. N Engl J Med 340 (1999) 858-868
5. Moller J., Connolly H., Rubin J., et al. Factors associated with progression of carcinoid heart disease. N Engl J Med 348 (2003) 1005-1015
6. Kunnimalaiyaan M., Vaccaro A.M., Ndiaye M.A., et al. Inactivation of glycogen synthase kinase-3β, a downstream target of the ref-1 pathway, is associated with growth suppression in medullary thyroid cancer cells. Mol Cancer Ther 6 (2007) 1151-1158
7. Platta C.S., Greenblatt D.Y., Kunnimalaiyaan M., et al. The HDAC inhibitor trichostatin A inhibits growth of small cell lung cancer cells. J Surg Res 142 (2007) 219-226
8. Younes N., Fulton N., Tanaka R., et al. The presence of K-12 ras mutations in duodenal adneocarcinomas and the absence of ras mutations in other small bowel adenocarcinomas and carcinoid tumors. Cancer 79 (1997) 1804-1808
9. Paraskevakou H., Saetta A., Skandalis K., et al. Morphological-histochemical study of intestinal carcinoids and K-ras mutation analysis in appendiceal carcinoids. Pathol Oncol Res B5 (1999) 205-210
10. Yashiro T., Fulton N., Hara H., et al. Comparison of mutations of ras oncogene in human pancreatic exocrine and endocrine tumors. Surgery 114 (1993) 758-763
11. Sippel R.S., Carpenter J.E., Kunnimalaiyaan M., et al. Ref-1 activation suppresses neuroendocrine marker and hormone levels in human gastrointestinal carcinoid cells. Am J Physiol Gastrointest Liver Physiol 285 (2003) G245-G254
12. Cheng X.C., Kihara T., Ying X., et al. A new antibiotic, tautomycetin. J Antibiot 42 (1989) 141-144
13. Shim J.H., Lee H.K., Chang E.J., et al. Immunosuppressive effects of tautomycetin in vivo and in-vitro via T cell-specific apoptosis induction. Proc Natl Acad Sci U S A 99 (2002) 10617-10622
14. Cip/Waf induction via the extracellular signal-regulated kinase pathway. Mol Cancer Ther 5 (2006) 3222-3231
15. Van Gompel J.J., Kunnimalaiyaan M., Holen K., et al. ZM336372, a ref-1 activator, suppresses growth and neuroendocrine hormone levels in carcinoid tumor cells. Mol Cancer Ther 4 (2005) 910-917
16. Woods D., Parry D., Cherwinski H., et al. Ref-induced proliferation of cell cycle arrest is determined by the level of ref activity with arrest mediated by p21Cip1. Mol Cell Biol 17 (1997) 5598-5611
17. Park K.S., Lee N.G., Lee K.H., et al. The ERK pathway involved positive and negative regulations of HT-29 colorectal cancer cell growth by extracellular zinc. Am J Physiol Gastrointest Liver Physiol 285 (2003) G1181-G1188
18. Sewing A., Wiseman B., Lloyd A.C., et al. High-intensity ref signal causes cell cycle arrest mediated by p21Cip1. Mol Cell Biol 17 (1997) 5588-5597
19. Kerkhoff E., and Rapp U.R. Cell cycle targets of ras/ref signaling. Oncogene 17 (1993) 1457-1462
20. Chen H., Kunnimalaiyaan M., and Van Gompel J.J. Medullary thyroid cancer: the functions of ref-1 and human achaete-scute homologue-1. Thyroid 15 (2006) 511-521
21. Chen H., Hardacre J.M., Uzar A., et al. Isolated liver metastases from neuroendocrine tumors: does resection prolong survival?. J Am Coll Surg 187 (1998) 88-92
22. Modlin I.M., Lye K.D., and Kidd M.A. 50-year analysis of 562 gastric carcinoids: small tumor or larger problem?. Am J Gastroenterol 99 (2004) 23-32
23. Godwin II J.D. Carcinoid tumors. An analysis of 2,837 cases. Cancer 36 (1975) 560-569
24. Lal A., and Chen H. Treatment of advanced carcinoid tumors. Curr Opin Oncol 18 (2006) 9-15
25. Hall-Jackson C.A., Eyers P.A., Cohen P., et al. Paradoxical activation of ref by a novel ref inhibitor. Chemico-Biological 6 (1999) 559-568
26. Mitsuhashi S., Matsuura N., Ubukata M., et al. Tautomycetin is a novel and specific inhibitor of serine/threonine protein phosphatase type 1, PPI. Biochem Biophys Res Commun 287 (2001) 328-331
27. Li W., Ju J., Osada H., et al. Utilization of the methoxy malonyl-acyl carrier protein biosynthesis locus for cloning of the tautomycin biosynthetic gene cluster from Streptomyces spiroverticillatus. J Bacteriol 188 (2006) 4148-4152